Endo International plc
Glandore Business Centres
No. 33 Fitzwilliam Square
Tel: 353-1-669-8559 or 800-462-3636
180 articles with Endo International plc
Endo International plc (NASDAQ: ENDP) will announce its second-quarter 2019 financial results on August 6, 2019 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET before the U.S. financial markets open.
Nationally Recognized Urologist and Author, Aaron Spitz, MD, Teams Up with Endo Pharmaceuticals' Ask About the Curve Campaign to Encourage Men to Get "In Touch" With Their Anatomy This Men's Health Month
Ask About the Curve raises awareness of Peyronie's disease, a men's health condition that may affect about 1 in 10 men and leads to a pronounced curvature in the penis and potential pain during arousal.
Phase 3 Data of Collagenase Clostridium Histolyticum for the Investigational Treatment of Cellulite to Be Presented at The Aesthetic Meeting 2019
Clinical Investigator Dr. Lawrence Bass is a Featured Hot Topics Speaker
Endo International plc announced that members of management will participate in a fireside chat at the RBC Annual Healthcare Conference in New York City on Tuesday, May 21, 2019 at 10:00 a.m. ET.
Endo International plc reported first-quarter 2019 financial results
Par Pharmaceutical, Inc. Issues Voluntary Nationwide Recall of One Lot of Mycophenolate Mofetil for Injection, USP Due to the Presence of a Glass Fragment Observed in One Vial of Reconstituted Product
One vial of product was observed containing a glass fragment after reconstitution.
Endo International plc will announce its first-quarter 2019 financial results on May 9, 2019 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET before the U.S. financial markets open.
Endo Begins Shipment of Authorized Generic Version of PROVENTIL® (albuterol sulfate) HFA Inhalation Aerosol in the United States
Endo International plc announced that one of its operating companies, Par Pharmaceutical, has begun shipping an authorized generic version of Merck's PROVENTIL® HFA Inhalation Aerosol, 120mcg.
Endo International plc Announces Early Tender Results of its Previously Announced Cash Tender Offers and Consent Solicitations for up to $1.5 billion Aggregate Purchase Price of its Outstanding Senior Notes
Endo International plc announced the early tender results of the previously announced cash tender offers made by Endo Finance LLC, a wholly-owned subsidiary of Endo International plc, for the debt securities listed in the table below.
Endo Announces Publication Of Collagenase Clostridium Histolyticum (CCH) Phase 2 Data In Dermatologic Surgery
Leading Peer-Reviewed Dermatology Journal Features Phase 2 Data
Endo International plc announced that Par Pharmaceutical, Inc., its wholly-owned subsidiary, priced $1.5 billion aggregate principal amount of 7.500% senior secured notes due 2027 at an issue price of $1,000 per $1,000 principal amount in connection with its previously announced private offering, which represents an upsize of $500.0 million over the previously contemplated offering amount.
Endo International plc announced an upsizing of its previously announced cash tender offers and consent solicitations by Endo Finance LLC, a wholly-owned subsidiary of Endo International plc.
Endo International plc (NASDAQ: ENDP) ("Endo") today announced that Par Pharmaceutical, Inc. (the "Issuer"), its wholly-owned subsidiary, intends to offer senior secured notes, subject to market and customary conditions
Endo International plc Announces Debt Refinancing Transactions, Including Cash Tender Offers and Consent Solicitations for up to $1.0 billion Aggregate Purchase Price of its Outstanding Senior Notes
Endo International plc (NASDAQ: ENDP) today announced a series of debt refinancing transactions that are intended to help manage the debt maturity profile of it and certain of its subsidiaries (collectively, the "Company" or "Endo"). These refinancing transactions are expected to include:
Endo International plc (NASDAQ: ENDP) announced today that members of management will participate in a fireside chat at the Cowen & Company 39th Annual Healthcare Conference in Boston, Massachusetts on Monday, March 11, 2019 at 2:10 p.m. ET.
Endo International plc announced that the U.S. Food and Drug Administration has determined that there is no clinical need to compound vasopressin under Section 503B of the Drug Quality and Security Act.
Endo Will Showcase Late-Breaking Phase 3 CCH Data at the 2019 American Academy of Dermatology Annual Meeting
Endo International plc (NASDAQ: ENDP) today announced that it will present new data showing collagenase clostridium histolyticum (CCH) significantly met the clinical endpoint of improved cellulite severity and appearance and was well tolerated in recent Phase 3 clinical trials.
Endo International plc reported fourth-quarter 2018 financial results
Endo Announces Termination of Acquisition Agreements with Somerset Therapeutics and Business of Affiliate Wintac Limited
Endo International plc announced that its subsidiaries, Endo Ventures Limited, Par Pharmaceutical, Inc.
Endo Agrees Not To Oppose Additional Stay of FDA Litigation Following Restoration of Government Appropriations
Endo International plc ("Endo") (NASDAQ: ENDP) today announced that the U.S. Food and Drug Administration (the "FDA") has requested a further stay of Endo's ongoing litigation against the FDA through March 15, 2019.